For a company sitting on nearly €17 billion in cash, BioNTech is navigating a remarkably precarious moment. The German biotech enters a packed May calendar with a radical restructuring plan, a looming competitor threat, and a shareholder meeting that will set the stage for its high-stakes pivot from pandemic profits to oncology leadership. The next few weeks will test whether the company’s financial firepower can outweigh the operational and competitive headwinds it faces.
A Quarter of Contradictions
BioNTech’s first-quarter results, released this week, painted a picture of a company in transition. Revenue collapsed to €118.1 million, a staggering 79% drop from the prior quarter when Covid vaccine sales still topped €900 million. The net loss widened to €531.9 million, though the per-share loss of $2.26 came in better than the $2.52 analysts had braced for. For the full year, management has guided for revenue between €2.0 billion and €2.3 billion, down from €2.9 billion in 2025.
The headline number, however, sits on the balance sheet: €16.8 billion in liquid assets. Alongside the earnings, the board announced a $1 billion share buyback program — a move that, combined with the elimination of up to 1,860 jobs, sent a mixed signal to the market. The restructuring targets sites in Idar-Oberstein, Marburg, Tübingen, and Singapore, with partial sales being explored to avoid outright closures.
Investors responded with caution. The Frankfurt-listed shares fell 3.8% to €81.90, trading just below their 200-day moving average of €87.62. Analysts remain split: HC Wainwright and Citigroup maintain buy ratings but trimmed price targets to $130, while Jefferies sees fair value at $138.
The Oncology Clock Is Ticking
Behind the financial noise, BioNTech’s strategic direction is becoming clearer. The company is racing to establish itself as a serious oncology player, targeting at least 15 ongoing Phase 3 trials by the end of 2026 and ten cancer drug approvals by 2030. More than 17 late-stage data readouts are planned through the end of the decade, with five due before year-end.
Early data on its lead bispecific antibody, Pumitamab, offers a glimpse of the potential. A confirmed response rate of 46% was reported across the program, rising to 71% in PD-L1-positive squamous non-small cell lung cancer — results that underpin the ongoing Phase 3 ROSETTA LUNG-02 trial.
Should investors sell immediately? Or is it worth buying BioNTech?
But the most consequential event of the month may come from outside the company. On May 31, partners Akeso and Summit will present overall survival data from the Phase 3 HARMONi-6 trial for Ivonescimab at the ASCO congress. That drug targets the same PD-L1/VEGF-A axis as Pumitamab, and strong results would intensify competitive pressure on BioNTech’s core program. US pharmaceutical tariffs of up to 100% add another layer of uncertainty that the company has yet to quantify.
Shareholder Meeting Sets the Governance Stage
On May 15, shareholders will vote on a series of proposals that signal the depth of BioNTech’s transformation. The board recommends carrying forward the entire retained profit of roughly €6.9 billion — no dividend is planned. The supervisory board is set to expand from six to eight members, adding two specialists in oncology and clinical development.
Perhaps most tellingly, management is seeking authorized capital of up to €129.5 million, representing about 50% of current share capital. The message is unambiguous: BioNTech is aligning its governance and capital structure for a long, expensive march into oncology.
The Analyst View
Wall Street remains cautiously constructive. The consensus price target translates to roughly €115, implying substantial upside from current levels. But the range is wide, reflecting uncertainty about the pace of the oncology transition and the competitive landscape. EPS estimates have risen about 5% over the past 60 days, while revenue forecasts have fallen 56% in the same period — a stark illustration of the post-pandemic reset.
The upcoming earnings call will be pivotal. Investors will be listening for credible defense of the oncology timeline and clarity on how quickly the company is burning through its cash pile. With a rival’s data due at the end of the month and a shareholder vote in between, May will determine whether BioNTech’s €17 billion war chest is a foundation for growth or a cushion for a difficult transition.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from May 5 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 5.
BioNTech: Buy or sell? Read more here...
